Kalshi and AppliedXL launch biopharma prediction markets with strict guardrails

Kalshi has launched a pilot suite of prediction markets on clinical trial outcomes and FDA regulatory decisions, in partnership with AppliedXL. The exchange says the goal is to make drug-development probabilities public, and to do so with contracts that settle against named public documents rather than private messages or sponsor spin.

The pilot is intentionally narrow. According to Kalshi, it is limited to late-stage trials because earlier-phase studies rely more on exploratory endpoints and carry greater insider-trading risk. Contracts are listed only after patient enrollment closes, and all traders in these markets must undergo employment verification.

Kalshi also says the markets remain subject to its existing ban on trading by anyone with material nonpublic information. The company said the design is meant to protect both market integrity and the integrity of the trials being priced.

AppliedXL provides the resolution infrastructure behind the markets. Its role is to collect and structure the relevant clinical and regulatory records, map them to the contract’s predefined resolution criteria, and produce a source-linked evidence package for Kalshi’s review.

Each contract names a public source that will resolve the bet. Kalshi says those sources can include the registered primary endpoint on ClinicalTrials.gov, an FDA approval letter, or an advisory committee vote record.

The companies say AppliedXL defines the criteria for reading those documents before trading begins, while Kalshi retains responsibility for final settlement under its exchange rules. AppliedXL says Kalshi decides which markets to list and sets the contract terms.

The exchange is pitching the products as a way to close a long-standing information gap in drug development. Kalshi says the odds that a drug will succeed are among the most valuable numbers in the economy and among the least visible, in part because much of the underlying data is locked away.

To support that case, Kalshi cites McKinsey’s estimate that it costs about $2.3 billion on average to bring a single drug to market. It also says that, as of the FDA’s April 2026 figures, roughly 30% of trials required to report results had posted none.

Kalshi says the contracts produce continuously updated public probabilities that reflect the weight of evidence, rather than the sponsor’s preferred messaging. The company says that lets investors, smaller developers, clinicians and patients read the same probability, instead of relying on privileged access.

AppliedXL frames the markets as a cleaner way to resolve scattered evidence. Its site says clinical-trial results often arrive in pieces across registries, filings and company statements, and that resolving a market means reconciling those pieces back to the primary source.

The partnership is also accompanied by a white paper, “Biopharma’s Public Probability: The State and Future of Prediction Markets in Drug Development.” AppliedXL says the report examines what happens when expectations about clinical trials and FDA decisions become publicly visible and financially traded.

The paper points to an early precedent. In 2003, Eli Lilly asked about 50 chemists, biologists and project managers to trade shares tied to six drug candidates. AppliedXL says that internal market identified the three candidates that would go on to become the most successful.

Kalshi and AppliedXL say they will study how the markets perform and how traders use them before any broader release. The pilot’s first listed contracts include whether AR1001’s POLARIS-AD Phase 3 trial will meet its primary endpoint in early Alzheimer’s disease, and whether the FDA will approve Gilead and Arcellx’s anito-cel for relapsed and refractory multiple myeloma.

Steptoe, in a client alert on the same day, said markets tied directly to clinical trial outcomes and FDA decisions may create new compliance and insider-trading concerns for prediction markets and pharmaceutical companies.